Cardiac involvement in thalassaemia major: altered atrial natriuretic peptide levels in asymptomatic patients

Area of Science:

• Cardiology
• Hematology
• Biochemistry

Background:

• Congestive heart failure is a leading cause of mortality in young adults with thalassaemia major.
• Early detection of cardiac involvement is crucial for managing thalassaemia major patients.

Purpose of the Study:

• To compare atrial natriuretic peptide (ANP) levels in asymptomatic thalassaemia major patients and healthy controls.
• To assess the correlation between ANP levels and left ventricular diastolic dysfunction.
• To evaluate ANP as a potential biomarker for pre-clinical cardiac involvement in thalassaemia major.

Main Methods:

• Cross-sectional study comparing 30 asymptomatic thalassaemia major patients (mean age 16.6 years) with 30 age- and sex-matched controls.
• Measurement of basal plasma atrial natriuretic peptide (ANP) levels.
• Assessment of plasmatic renin activity, aldosterone, urinary sodium, and catecholamine levels.
• Evaluation of ANP response to blood volume stimulation (transfusion).
• Doppler echocardiography to identify left ventricular diastolic dysfunction.

Main Results:

• ANP levels were significantly higher in thalassaemia major patients (93.9 pg/mL) compared to controls (51.8 pg/mL; P < 0.001).
• Basal ANP levels above two standard deviations of control values correlated with diastolic dysfunction (57% sensitivity, 91% specificity).
• ANP levels increased after blood transfusion in thalassaemic patients, indicating maintained response to volume overload.

Conclusions:

• Elevated basal ANP levels in asymptomatic thalassaemia major patients suggest initial myocardial involvement.
• ANP may serve as a sensitive biomarker for detecting pre-clinical cardiac dysfunction in thalassaemia major.
• Further studies are needed to establish the clinical and prognostic significance of these findings.